Latest Articles
Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production
Entrada Therapeutics has announced positive initial results from its...
Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study
Entrada Therapeutics has received clearance to test the highest...
Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne
Sapreme Therapeutics has announced promising preclinical results for SPM-2551,...
Most Popular
Frequently Asked Questions About Elevidys Used for DMD
Duchenne muscular dystrophy (DMD) is a genetic condition that...
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
The landscape of potential new gene therapies for Duchenne...
The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control
The duchenne muscular dystrophy treatment cost has become one...
© 2024 - 2026 DMD Warrior. All rights reserved.